Increasing access to multidisciplinary

teams to support entry and adherence to HIV and HCV treatment will be essential to tackle the health needs of this population. This will be increasingly important as newer, more effective direct-acting HCV therapies become available. Strengths of our study include the very large number of diverse participants who are broadly representative of the Canadian coinfected population in care, careful outcome ascertainment and relatively low numbers lost to follow-up. Better ascertainment of deaths through linkage to administrative databases and careful data verification may partly explain the higher death rates we observed compared with previous studies. Even selleck so, we may have actually underestimated true mortality rates as we were unable to fully determine whether those lost to follow-up had died. Our study was, however, restricted to patients engaged in care in urban and semi-urban settings. Thus, the rates of risk behaviours and treatment and health outcomes may not fully represent the experience of the wider coinfected population who may not be accessing medical Erastin mouse care regularly. Therefore, our findings, while alarming, may actually represent an underestimate

of the true disease burden from experienced by HIV/HCV-coinfected patients. Self-report may also underestimate the degree and extent of risk behaviours. Our findings highlight that interventions aimed at improving social circumstances, reducing harm from drug and alcohol use and increasing the delivery of HCV treatment in particular will be necessary to reduce adverse health outcomes

and limit the looming epidemic of ESLD among HIV/HCV-coinfected persons and consequent mortality. Continued research is needed to evaluate the impact of therapies on disease progression, health service utilization and costs and how to better target preventive measures and treatment services for coinfected persons with the aim of reducing the individual and population burden of this important comorbidity. This study was funded by the Fonds de recherche en santé du Québec, Réseau SIDA/maladies infectieuses (FRSQ), the Canadian Institutes of Health Research (CIHR MOP-79529) and the CIHR Canadian HIV Trials Network (CTN222). EM is supported by a University Faculty Award from the Natural Sciences and Engineering Research Council of Canada. MBK is supported by a Chercheur-Boursier clinicien senior career award from the FRSQ. CC is supported by an Ontario HIV Treatment Network for Career Scientist Award.

No related posts.